-
ABOUT USAffiliated to SSY Group Limited, Hebei Guangxiang Technology Co., Ltd., is a high-tech enterprise specializing in drug research and technology development.
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the synergy between “industry, academia, research and application” based on multi-disciplinary integration and multi-directional combination.
-
SUBORDINATEThe group has decided to establish research institutes in its subsidiaries, Hebei Ghuangxiang Drug Research Institute, Jiangsu Best Medical Material Research Institute, and Hebei Hanlin Biological Research Institute.
-
RECRUITWe actively establish a joint talent cultivation mechanism between schools and enterprises, and currently have over 500 high-level talents in various fields such as drug research, analysis, and clinical practice.
-
CONTACTWe will continue to strengthen innovation-driven development, vigorously promote the integration of production and research, constantly improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs.
The company reaped abundant rewards at the 2019 China Chemical Pharmaceutical Industry Annual Summit.
Category:
Time：2019-10-29
On October 10, the "2019 China Chemical Pharmaceutical Industry Annual Summit and the Launching Ceremony of the 'Pharmaceutical Industry Blue Book'" was held in Nanchang, where the company once again received several prestigious awards. Shi Jianhui, Secretary of the Party Committee of the company, was invited to attend the conference.
On October 10, the “2019 China Chemical Pharmaceutical Industry Annual Summit and the Launching Ceremony of the ‘Pharmaceutical Industry Blue Book’” were held in Nanchang, where the company once again received several prestigious awards. Shi Jianhui, Secretary of the Party Committee of the company, was invited to attend the conference.
During the conference, the launch ceremony for the “2019 Pharmaceutical Industry Blue Book” published by the China Association of Chemical Pharmaceutical Industry was held. Wen Zaixing, former director-general of the Ministry of Commerce, delivered a speech at the launch ceremony. Qu Jiguang, Chairman of the company, served as the executive chief editor of the book. The “2019 Pharmaceutical Industry Blue Book” comprises 12 major chapters, divided into sections covering the general report, pharmaceutical reform, policies and regulations, industry development, special reports, technological innovation, quality standards, green pharmaceutical practices, credit building, regional development, international exchanges, and an appendix. This book focuses on in-depth analysis and research into the development of the pharmaceutical industry and related hot topics. It is characterized by its authority, comprehensiveness, systematic approach, and practicality, making it a valuable reference resource both within and beyond the industry.
Meanwhile, during the conference, the list of “2019 Outstanding Enterprises and Brand Products in China’s Chemical Pharmaceutical Industry,” jointly recommended and organized by the China Association of Chemical Pharmaceutical Industry, the China Pharmaceutical Commerce Association, the China Over-the-Counter Drug Association, the China Pharmaceutical Enterprise Development Promotion Association, and Sinopharm Expo Co., Ltd., was released. At the conference, the company received a total of five honors: Top 100 Comprehensive Strength Enterprises in China’s Chemical Pharmaceutical Industry for 2019; Outstanding Export-Oriented Enterprise Brand in China’s Chemical Pharmaceutical Industry for 2019; Outstanding Enterprise Brand for Promoting Integration of Informatization and Industrialization in China’s Chemical Pharmaceutical Industry for 2019; Outstanding Product Brand in the Category of Water, Electrolyte, Acid-Base Balance Regulation, Minerals, and Nutritional Supplements in China’s Chemical Pharmaceutical Industry for 2019; and Outstanding Product Brand in the Category of Blood and Hematopoietic System Products in China’s Chemical Pharmaceutical Industry for 2019.
The summit has been held continuously for nine sessions since 2011. This year’s summit features a thematic forum centered on “Quality, Integrity, and Brand.” The summit is attended by representatives from relevant government departments, provincial and municipal pharmaceutical industry associations, pharmaceutical manufacturing companies, and upstream and downstream enterprises in the pharmaceutical sector.
For many years, the company has consistently adhered to the philosophy of “Technology Creates the Future,” successfully achieving intelligent transformation of its production workshops. By leveraging technology to enhance product quality, the company has earned recognition from both the market and various sectors of society, driving its overall business development. The product portfolio has continued to diversify, with the proportion of high-value-added products steadily increasing, thereby strengthening the company’s market appeal and enabling it to export its products to over 80 countries and regions. As a result, the company’s brand value has further increased, its brand influence has grown stronger, and its industry reputation has been steadily improving.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Mobile site
E code
Business license